Fig. 4From: Could potentially calprotectin be a promising biomarker to oracle biologic therapy response in rheumatoid arthritis?Receiver operating characteristic (ROC) curve for serum calprotectin levels before and after biologic therapy. Before starting bDMARDs, the area under the curve (AUC) was 0.654 (95% CI 0.437–0.872); P = 0.221, whereas after therapy, the AUC was 0.522 (95% CI 0.252–0.792); P = 0.861Back to article page